Rethinking checkpoint blockade for cancer treatment
Funded by the European Union’s Horizon Europe Innovation Council.
2022 Pathfinder Open program.
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101098965. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them
Latest news and events
-
First year of REPRESSIT
In the complex world of cancer, immune cells called T cells are a critical part of our bodies’ arsenal to combat tumor cells. They play a crucial role in “finishing the job” when patients are treated for cancer with chemotherapy or radiation. Unfortunately, in some patients, these cells are often ‘shut down’ by inhibitory immune…
No news yet
Our motivation
REPRESSIT will generate a technology platform for off-the-shelf RIPR molecules (Receptor Inhibition by Phosphatase Recruitment) targeting any tyrosine phosphatase carrying inhibitory immune receptor.
The REPRESSIT consortium will create a Proof-of-Concept for full in vivo functionality of RIPR molecules against diverse T and NK cell receptors in preclinical tumor models.
Our expected outcomes will provide the foundation for our long-term vision of novel immune checkpoint therapeutics with unprecedented efficacy for more cancer patients.
Partners
This project brings together a range of research disciplines, including tumor immunologists, protein engineering experts, biochemists, biophysicists, and mass spectrometry specialists.
Reach us!
You can talk to us using contact@repressit.eu or you can reach out any of our main researchers.
Selected publications
- Immune receptor inhibition through enforced phosphatase recruitment.
Nature. 2020 Oct; 586(7831):779-784.
Fernandes RA, Su L, Nishiga Y, Ren J, Bhuiyan AM, Cheng N, Kuo CJ, Picton LK, Ohtsuki S, Majzner RG, Rietberg SP, Mackall CL, Yin Q, Ali LR, Yang X, Savvides CS, Sage J, Dougan M, Garcia KC. - The K2: Open-source simultaneous triple-color TIRF microscope for live-cell and single-molecule imaging.
Hardware X. 2023, 1, 2468
Christian Niederauer, Marco Seynen, Jan Zomerdijk, Marko Kamp, Kristina A. Ganzinger. - Miniaturized and multiplexed high-content screening of drug and immune sensitivity in a multichambered microwell chip.
Cell Rep Methods. 2022 Jul 18;2(7):100256.
Sandström N, Carannante V, Olofsson K, Sandoz PA, Moussaud-Lamodière EL, Seashore-Ludlow B, Van Ooijen H, Verron Q, Frisk T, Takai M, Wiklund M, Östling P, Önfelt B. - Modulation of lytic molecules restrain serial killing in γδ T lymphocytes.
Nat Commun 14, 6035 (2023).
Patrick A Sandoz, Kyra Kuhnigk, Edina K Szabo, Sarah Thunberg, Elina Erikson, Niklas Sandström, Quentin Verron, Andreas Brech, Carsten Watzl, Arnika K Wagner, Evren Alici, Karl-Johan Malmberg, Michael Uhlin, Björn Önfelt.
